A phase 2, placebo-controlled, randomized, double blind, parallel arm, dose ranging study to evaluate safety and efficacy of apixaban in patients with a recent acute coronary syndrome.

Trial Profile

A phase 2, placebo-controlled, randomized, double blind, parallel arm, dose ranging study to evaluate safety and efficacy of apixaban in patients with a recent acute coronary syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Apixaban (Primary)
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms APPRAISE-1
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
    • 09 Jun 2009 Results published in Circulation 119: 2877-2885, No. 22, 9 Jun 2009.
    • 26 Sep 2008 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top